FIGURE 4.

Wnt/β‐catenin signalling pathway in OA‐FLS inflammation. FoxC1, a target gene of miR‐200a‐3p, promoted human OA‐FLS proliferation, pro‐inflammatory cytokine and catabolic enzymes expression by elevated β‐catenin production. IL‐1β inhibited miR‐200a‐3p enhanced the effects of FoxC1 in human OA‐FLS. XAV‐939, a small‐molecule inhibitor of Wnt pathway, reduced proliferation and I collagen levels of OA‐FLS. Lorecivivint, a small‐molecule Wnt pathway inhibitor, declined pro‐inflammatory cytokines by inhibiting NF‐κB and STAT3 phosphorylation through reduced CLK2 and DYRK1A production in human OA‐FLS. LRP5/6: Lipoprotein receptor‐associated protein; GSK3β: Glycogen synthase kinase 3β; CK1: Casein kinase 1; APC: Adenomatous polyposis coli; LEF/TCF: Lymphoid enhancer factor/T‐cell; CLK2: CDC‐like kinase 2; DYRK1A: Dual‐specificity tyrosine phosphorylation‐regulated kinase 1A